|
Harald Isemann: Building an Optimal Framework for World-Class Biotechnology Research |
|
|
|
by Eleonora Windisch
Administrative Director
Research Institute of Molecular Pathology (IMP)
Vienna, Austria
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Harald Isemann was named
Administrative Director of the privately-funded Institute of Molecular
Pathology (IMP) in Vienna in February 2004. IMP is a subsidiary of
Boehringer Ingelheim, one of the world’s leading pharmaceutical
companies. Headed by Prof. Kim Nasmyth, the Institute is a basic
biomedical research center and is located within the Campus Vienna
BioCenter, a center for molecular biology and genetic research. “My
experience working with Technologie Impulse Ltd. (TIG), enabled me to
acquire the necessary expertise for my current position at IMP,” Mr.
Isemann said, adding, “IMP’s reputation as one of Europe’s leading
research institutions made the job offer particularly attractive for
me.”
Access to
the full article is free, but requires you to register. Registration is
simple and quick – all we need is your name and a valid e-mail address.
We appreciate your interest in bridges.
|